Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has granted restricted stock units (RSUs) to two new non-executive employees. The RSUs, representing 30,400 shares of common stock, were approved by the Compensation Committee and granted under the Company's Amended and Restated Inducement Equity Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, with 25% vesting annually, contingent on continued employment.

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2025 the Company granted restricted stock units (RSUs) representing 30,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

FAQ

How many shares of FATE stock were granted as RSUs on May 1, 2025?

Fate Therapeutics granted RSUs representing 30,400 shares of common stock to two new non-executive employees.

What is the vesting schedule for Fate Therapeutics' RSUs granted in May 2025?

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to continuous employment.

Under which rule were FATE's employee inducement awards granted?

The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) under the Company's Amended and Restated Inducement Equity Plan.

What type of company is Fate Therapeutics (FATE)?

Fate Therapeutics is a clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.